论文部分内容阅读
目的:观察清肺合剂联合化疗治疗老年晚期非小细胞肺癌(NSCLC)临床疗效。方法:选择2008年1月-2010年12月间收治的经确诊的初治晚期NSCLC患者73例,分别入清肺合剂联合GP方案化疗(治疗组)33例和单纯GP方案化疗(对照组)40例,入组患者至少接受2个周期以上的化疗。结果:入组的73例患者均可评价疗效,治疗1年后随访,治疗组33例,对照组37例,失访3例。治疗组和对照组总有效率分别是33.33%和20.00%,中位生存期为16.6个月和15.1个月,1年生存率为75.76%和59.46%,2年生存率为18.18%和16.22%,两组差异无统计学意义。治疗后,治疗组在KPS评分、临床症状改善及化疗毒副作用方面均优于对照组(P<0.05)。结论:清肺合剂联合化疗治疗老年晚期非小细胞肺癌,在改善患者的临床症状,提高患者的生活质量,减轻化疗的毒副反应等方面具有临床意义。
Objective: To observe the clinical effects of Qingfei mixture combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Seventy-three patients with newly diagnosed advanced NSCLC who were admitted between January 2008 and December 2010 were enrolled in this study. Thirty-three patients with lung-cancer combined with GP regimen (treatment group) and 31 patients with simple GP regimen (control group) Forty patients were enrolled and received at least 2 cycles of chemotherapy. Results: All the 73 patients in the study group were evaluated. After one year follow-up, 33 cases in the treatment group, 37 cases in the control group, and 3 cases in the lost group. The total effective rate of treatment group and control group were 33.33% and 20.00%, respectively. The median survival time was 16.6 months and 15.1 months. The 1-year survival rates were 75.76% and 59.46%, and the 2-year survival rates were 18.18% and 16.22% , No significant difference between the two groups. After treatment, the treatment group was better than the control group in KPS score, clinical symptoms and chemotherapy side effects (P <0.05). Conclusion: Qingfei Mixture combined with chemotherapy for advanced non-small cell lung cancer has clinical significance in improving clinical symptoms, improving patients’ quality of life and alleviating the side effects of chemotherapy.